Drug Profile


Alternative Names: AB-1010; Masican; Masitinib mesilate; Masitinib mesylate; Masiviera

Latest Information Update: 02 Jun 2017

Price : $50

At a glance

  • Originator AB Science
  • Class Antiasthmatics; Antineoplastics; Antirheumatics; Benzamides; Nootropics; Piperazines; Pyridines; Small molecules; Thiazoles
  • Mechanism of Action Colony stimulating factor inhibitors; Focal adhesion protein-tyrosine kinase inhibitors; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor receptor antagonists; Protein tyrosine kinase inhibitors; Proto oncogene protein c-kit inhibitors; Type 3 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mastocytosis; Gastrointestinal stromal tumours; Amyotrophic lateral sclerosis; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Amyotrophic lateral sclerosis; Mastocytosis
  • Phase III Alzheimer's disease; Asthma; Colorectal cancer; Gastrointestinal stromal tumours; Malignant melanoma; Multiple myeloma; Pancreatic cancer; Peripheral T-cell lymphoma; Prostate cancer
  • Phase II/III Crohn's disease; Multiple sclerosis; Ovarian cancer; Progressive supranuclear palsy
  • Phase II Breast cancer; Chronic obstructive pulmonary disease; Head and neck cancer; Mood disorders; Non-small cell lung cancer; Parkinson's disease
  • Phase I/II Gastric cancer; Glioblastoma; Hepatocellular carcinoma; Oesophageal cancer
  • Preclinical Stroke
  • No development reported Psoriasis
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 02 Jun 2017 AB Science plans a phase III trial for Asthma in Thailand (TCTR20161129004)
  • 19 May 2017 CHMP adopts negative opinion for approval of masitinib for Mastocytosis in European Union
  • 27 Apr 2017 AB Science plans a phase III trial for Amyotrophic lateral sclerosis(Combination therapy) (NCT03127267)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top